{"id":"gsk256066","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypotension"},{"rate":"5-10%","effect":"Bradycardia"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL5307584","moleculeType":null,"molecularWeight":"632.62"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the ryanodine receptor 2, GSK256066 reduces the intracellular calcium release from the sarcoplasmic reticulum, leading to a decrease in cardiac contractility and a reduction in heart rate. This mechanism is thought to be beneficial in the treatment of atrial fibrillation.","oneSentence":"GSK256066 is a selective and potent inhibitor of the cardiac ryanodine receptor 2.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:40:03.729Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT00464568","phase":"PHASE2","title":"A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-28","conditions":"Rhinitis, Allergic, Seasonal","enrollment":32},{"nctId":"NCT00515268","phase":"PHASE1","title":"Endotoxin Challenge Study For Healthy Men and Women","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09-27","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":37},{"nctId":"NCT00549679","phase":"PHASE2","title":"Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":104},{"nctId":"NCT00549744","phase":"PHASE2","title":"Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11-16","conditions":"Asthma","enrollment":78},{"nctId":"NCT00612820","phase":"PHASE2","title":"A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01","conditions":"Rhinitis, Allergic, Seasonal","enrollment":55},{"nctId":"NCT00377728","phase":"PHASE2","title":"Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-03","conditions":"Rhinitis, Allergic, Seasonal, Seasonal Allergic Rhinitis","enrollment":44},{"nctId":"NCT00612118","phase":"PHASE2","title":"A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02","conditions":"Allergic Rhinitis, Rhinitis, Allergic, Seasonal","enrollment":70},{"nctId":"NCT00380354","phase":"PHASE2","title":"Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09","conditions":"Asthma, Mild Asthma","enrollment":11},{"nctId":"NCT00445510","phase":"PHASE2","title":"This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive Asthmatics Against an Antigen Challenge","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06","conditions":"Asthma","enrollment":24},{"nctId":"NCT00430157","phase":"PHASE2","title":"Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01","conditions":"Rhinitis, Allergic, Seasonal, Seasonal Allergic Rhinitis","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GSK256066","genericName":"GSK256066","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GSK256066 is a selective and potent inhibitor of the cardiac ryanodine receptor 2. Used for Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}